JMP Securities analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and lowers the price target from $397 to $381.
JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $381
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.